In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $97.2 which represents a slight increase of $0.25 or 0.26% from the prior close of $96.95. The stock opened at $96.73 and ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...

In the latest market close, Gilead Sciences (GILD) reached $98.38, with a +1.21% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...